Ginkgo Bioworks Hldgs Inc DNA

$7.97 -0.53 (-6.24%)

Valuation

Market cap
555,254,000
Revenue TTM
$170,160,000
Net income TTM
$-312,760,000
PE ratio
0.00
Forward PE
—
Profit margin
-183.80%
Debt to equity
0.00

Trading

Volume
1,653,600
Avg volume
1,173,662
Day's range
$7.49 – $8.37
Shares out
65,324,000
Stochastic %K
31%
Beta
1.78
Analysts
Hold
Price target
$8.67

Price

Company profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence mode...

Show more

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
877 422 5362
Website
https://www.ginkgo.bio
Address
27 Drydock Avenue, 8th Floor, Boston, United States

Latest news

Stocktwits

Ramseydog Oct 3, 10:31 PM
$DNA AbbVie, argenx, Lundbeck, and Takeda just signed on as founding members of the antibody consortium. Lilly TuneLab and the Novo Waltham autonomous lab already in the mix. Data plus labs. Still like the setup. 💪 #DNA #Ginkgo
0 replies
WantedToRetireEarly Oct 2, 5:39 PM
$DNA decided to take a small position here after many years to follow the stock. Lost a ton on AMRS but made up a little of those losses with $TWST DNA has been a disaster as a stock but the rise of AI and the new business model around automated labs may be the business model that finally works. Way too early to tell but I like the fact that NOVO and Lilly see something here. Clearly the market sees this going to zero and I get it given its past failures. But worth following now for the first time in years.
0 replies
WantedToRetireEarly Oct 2, 3:31 PM
$DNA a good write up. This company has been one of tbe biggest destroyers of capital I’ve ever seen. But they have a new business model and some big new partners like Novo. This time do they have a real business to sell? https://x.com/metavestor/status/2103218347475337499
0 replies
WantedToRetireEarly Oct 2, 12:26 PM
$DNA the CEO is answering questions here. Interesting conversations https://www.reddit.com/r/ginkgobioworks/s/OmgwKh9UJN
0 replies
Freddy7672 Oct 2, 3:20 AM
$DNA Short it scum CEO
1 replies
Ramseydog Oct 1, 4:53 PM
$DNA
0 replies
Moonman321 Oct 1, 3:02 PM
$DNA
0 replies
jaydilks Oct 1, 11:52 AM
$DNA Making 88% in a month feels great. The next 6 months tend to be brutal. Just be aware of the risk.
2 replies